Lupin gets USFDA approval for Mild Atopic dermatitis treatment lotion
New Delhi: Drug major Lupin recently stated it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion, used for the treatment of mild atopic dermatitis in patients 3 months of age and older, in the US market.
The approved product is a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1 percent, Lupin said in a BSE filing.
As per IQVIA MAT data of April 2018, Lupin said the product had annual sales of around USD 13.8 million in the US.
Shares of Lupin were trading 0.77 percent higher at Rs 876.50 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd